Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGLBiotechnology
-$1.33 today
- Market cap
- $9.25B
- Beta
- -1.06
- P/E (TTM)
- -46.9
- EPS (TTM)
- -$10.66
Volume 0.64M
Average 0.31M
MDGL Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Madrigal Pharmaceuticals, Inc.NASDAQ: MDGL
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow grows, but more slowly than its trailing trend
Q2 FY2026 financing cash flow of $3.11M rose 78.7% year over year, behind the +567.4% change in trailing-twelve-month financing cash flow. Sequentially, it rose 33.6% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.
Context
- Financing cash flow amounted to 26.7% of revenue in FY2025, down 381.4 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +78.7% toward the trailing-twelve-month pace of +567.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 255.98M USD
- Year-over-year change
- -65.2%
- 4-year CAGR
- +10.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 255.98M | -65.2% |
| FY2024 | 2024-12-31 | 735.06M | +23.5% |
| FY2023 | 2023-12-31 | 595.12M | +89.9% |
| FY2022 | 2022-12-31 | 313.45M | +83.1% |
| FY2021 | 2021-12-31 | 171.24M | — |
Financing Cash Flow vs competitors
How MDGL compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +567.4% is the 3rd highest of 7, against a peer median of +262.7%.
- Financing cash flow amounts to 19.6% of revenue for MDGL, versus a peer median of 3063.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $251.49M USD | +466.1% | +53.9% | 698594.4% | |
| LTM Jun 2026 | $251.04M USD | +567.4% | -6.5% | 19.6% | |
| FY2025 | €232M EUR | +59.4% | +84.0% | 5175.1% | |
| LTM Mar 2026 | $190.32M USD | -2.7% | +442.1% | 951.6% | |
| LTM Jun 2026 | $111.25M USD | +2441.0% | +163.8% | — | |
| LTM Jun 2026 | $41.68M USD | -91.1% | -57.8% | 585.3% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $275K USD | +1118.5% | — | — |
| Peer median (excluding MDGL) | — | +262.7% | +84.0% | 3063.4% | |
Competitors are the stored peer set for MDGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (241.85M) | (295.35M) | (373.63M) | (465.89M) | (288.28M) |
| Depreciation & Amortization | 405K | 467K | 527K | 1.1M | 1.51M |
| Deferred Income Tax | (7.32M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.87M | 31.63M | 49.74M | 79.88M | 98.13M |
| Change in Working Capital | 30.65M | 37.6M | (3.28M) | (72.35M) | (8.5M) |
| Accounts Receivables | 0 | 0 | 0 | (53.82M) | (80.65M) |
| Inventory | 0 | 0 | 0 | (34.07M) | (36.98M) |
| Accounts Payables | 20.36M | 2.45M | 4.21M | 15.56M | 5.28M |
| Other Working Capital | 10.29M | 35.15M | (7.49M) | (13K) | 103.86M |
| Other Non-Cash Items | 7.32M | 797K | 2.41M | 1.69M | 7.59M |
| Operating Cash Flow | (183.92M) | (224.86M) | (324.23M) | (455.57M) | (189.55M) |
| Capital Expenditures | (209K) | (217K) | (1.48M) | (1.46M) | (467K) |
| Acquisitions (Net) | 787K | (3K) | 0 | 0 | 0 |
| Purchases of Investments | (394.12M) | (143.48M) | (834.44M) | (1.13B) | (1.05B) |
| Sales of Investments | 389.27M | 350.38M | 333.4M | 839.19M | 1.09B |
| Other Investing Activities | (787K) | 3K | 0 | 19.09M | (8.97M) |
| Investing Cash Flow | (5.06M) | 206.69M | (502.52M) | (274.39M) | 32.32M |
| Debt Repayment | 0 | 50M | 65M | 0 | 217.93M |
| Common Stock Issued | 170.21M | 255.38M | 260.19M | 397.49M | 38.06M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.03M | 8.07M | 269.93M | 337.58M | 0 |
| Financing Cash Flow | 171.24M | 313.45M | 595.12M | 735.06M | 255.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 13K |
| Net Change in Cash | (17.74M) | 295.28M | (231.63M) | 5.1M | 98.76M |
| Free Cash Flow | (184.13M) | (225.07M) | (325.71M) | (457.03M) | (190.02M) |
Madrigal Pharmaceuticals, Inc.
NASDAQ:MDGL
Intrinsic Alpha fair value
Locked
Current Price
$398.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.